Eli Lilly's acquisition of Kelonia Therapeutics for $3.25 billion signifies a major investment in cancer biotechnology.

Technology Economics Corporate AcquisitionsApr 20, 2026score 0.172 posts · 0 replies across 1 instances

The thread discusses Eli Lilly's acquisition of Kelonia Therapeutics for $3.25 billion, highlighting a significant deal in the biotech industry. The posts are categorized under both Market News and Technology, indicating the deal's relevance to both financial and technological sectors.

Claims

Parent: BiotechnologyEntity: Eli LillySub-entity: Kelonia TherapeuticsImpact: positiveDate: Apr 20, 2026Target: Eli Lilly's acquisition of Kelonia Therapeutics for $3.25 billion

Source posts

@[email protected]

[Technology] Eli Lilly Strikes Deal for Cancer Biotech
The deal for Kelonia Therapeutics is valued at $3.25 billion upfront. #WSJ
https://www.wsj.com/tech/biotech/eli-lilly-nears-deal-for-cancer-biotech-db07be72?mod=rss_Technology
(Mon, 20 Apr 2026 13:35:00 GMT)

0 boosts · 0 favs · 0 replies · Apr 20, 2026

#wsj

@[email protected]

[Market News] Eli Lilly Strikes Deal for Cancer Biotech
The deal for Kelonia Therapeutics is valued at $3.25 billion upfront. #WSJ
https://www.wsj.com/tech/biotech/eli-lilly-nears-deal-for-cancer-biotech-db07be72?mod=rss_markets_main
(Mon, 20 Apr 2026 13:35:00 GMT)

0 boosts · 0 favs · 0 replies · Apr 20, 2026

#wsj